TGCT is a debilitating disease that often impacts patients in the prime of their lifeDesignation to include both localized and diffuse forms of the diseaseDUBLIN, Aug. 31, 2022 /PRNewswire/
/PRNewswire/ SynOx Therapeutics Limited ("SynOx" or the "Company"), the late-stage clinical biopharmaceutical company, announces a regulatory update on.